IFNγ ELISpot Analytical Validation (DFCI)
BRD ID: 3,464
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 2
Description
This analytical validation and performance report describes the methods used to validate the IFNγ ELISpot assay. The accuracy, precision, analytical sensitivity, analytical specificity and reportable ranges of the assay were evaluated using thawed peripheral blood mononuclear cells (PBMC) stimulated with negative controls (an irrelevant HIV-GAG peptide at 10 μg/mL, in DMSO vehicle), positive controls (CEF peptide pool containing 32 dominant CMV/EBV/influenza epitopes recognized by most human donors or PHA) and test antigens (peptide pools derived from tumor-associated antigens, patient-specific neoantigens, or vaccine antigens). It is used by the Cancer Immune Monitoring and Analysis Center (CIMAC) at Dana Farber Cancer Institute (DFCI). It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/research/networks/precision-medicine-oncology/cimac-cidc).
Documents for Download
DFCI CIMAC_ELISpot_validation_2026_508C.pdf [Size: 469 KB]Biospecimens
- Cell - Blood
- Cell - White Cells
Diagnoses
- General
- Not specified
Topics
- Platform-specific Methodology
Associated SOP Compendiums
- Platform-specific Methodology